AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15136961 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 32
Study 15136961 — intervention group
Group type: COMPARATOR
Intervention: Containment
Number of subjects: 32
Study 11682283 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 9
Study 11682283 — intervention group
Group type: COMPARATOR
Intervention: diphenhydramine (active control)
Number of subjects: 9
Study 9440175 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral LASIK
Number of subjects: 254
Study 9440175 — intervention group
Group type: COMPARATOR
Intervention: Sequential bilateral LASIK
Number of subjects: 254
Study 7944444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) < 30 mg/m2
Number of subjects: 134
Study 7944444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) >= 30 - < 40 mg/m2
Number of subjects: 134
Study 7944444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) >= 40 - < 50 mg/m2
Number of subjects: 134
Study 7944444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) >= 50 - < 60 mg/m2
Number of subjects: 134
Study 7944444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) >= 60 mg/m2
Number of subjects: 134
Study 3608652 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 3608652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3608652 — intervention group
Group type: COMPARATOR
Intervention: Normal comparison boys
Number of subjects: 0
Study 29307112 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg/day of chromium for 8 weeks
Number of subjects: 40
Study 27494260 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 vaccine
Number of subjects: 4
Study 27494260 — intervention group
Group type: EXPERIMENTAL
Intervention: Healive®
Number of subjects: 4
Study 27494260 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix®
Number of subjects: 4
Study 27494260 — intervention group
Group type: COMPARATOR
Intervention: hepatitis B vaccine
Number of subjects: 4
Study 25626016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lewis negative subjects
Number of subjects: 223
Study 25626016 — intervention group
Group type: COMPARATOR
Intervention: Le(a-b+) group
Number of subjects: 223
Study 22544837 — intervention group
Group type: EXPERIMENTAL
Intervention: Community program targeting smoking cessation
Number of subjects: 388
Study 20095912 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: reduced energy, fat and sucrose
Number of subjects: 126
Study 20095912 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: reduced energy and fat only
Number of subjects: 126
Study 20095912 — intervention group
Group type: COMPARATOR
Intervention: Group 3: control
Number of subjects: 126
Study 18387162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol once weekly (Group 1)
Number of subjects: 21
Study 18387162 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alfacalcidol twice weekly (Group 2)
Number of subjects: 21
Study 16627223 — intervention group
Group type: EXPERIMENTAL
Intervention: ertapenem 1 g daily
Number of subjects: 370
Study 16627223 — intervention group
Group type: COMPARATOR
Intervention: piperacillin/tazobactam 13.5 g daily in 3-4 divided doses
Number of subjects: 370
Study 16627223 — intervention group
Group type: EXPERIMENTAL
Intervention: ertapenem
Number of subjects: 370
Study 16627223 — intervention group
Group type: COMPARATOR
Intervention: piperacillin/tazobactam
Number of subjects: 370
Study 12682719 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg bolus followed by 12 mg/kg/h continuous infusion
Number of subjects: 100
Study 12682719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 100
Study 11053065 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar approach to the epidural space
Number of subjects: 200
Study 11053065 — intervention group
Group type: COMPARATOR
Intervention: Caudal approach to the epidural space
Number of subjects: 200
Study 8962902 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide and conventional handling
Number of subjects: 99
Study 8962902 — intervention group
Group type: COMPARATOR
Intervention: Conventional handling
Number of subjects: 99
Study 1433889 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (IPM) (1.0‐1.5 g/day)
Number of subjects: 95
Study 1433889 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam (AZT) (4 g/day) + Lincomycin (LCM) (1,200‐2,400 mg/day)
Number of subjects: 95
Study 1433889 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (IPM)
Number of subjects: 95
Study 1433889 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam (AZT) + Lincomycin (LCM)
Number of subjects: 95
Study 4008815 — intervention group
Group type: EXPERIMENTAL
Intervention: lodoxamide tromethamine, 0.25 mg four times daily
Number of subjects: 68
Study 4008815 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study 30458187 — intervention group
Group type: EXPERIMENTAL
Intervention: EG110 (110% MAV)
Number of subjects: 39
Study 30458187 — intervention group
Group type: EXPERIMENTAL
Intervention: EG100 (100% MAV)
Number of subjects: 39
Study 30458187 — intervention group
Group type: COMPARATOR
Intervention: CG100 (Control Group 100% MAV)
Number of subjects: 39
Study 30458187 — intervention group
Group type: COMPARATOR
Intervention: CG110 (Control Group 110% MAV)
Number of subjects: 39
Study 28982691 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1021
Study 27112322 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental agents in the MIDAS trial
Number of subjects: 0
Study 27112322 — intervention group
Group type: COMPARATOR
Intervention: Control arm with standard therapy
Number of subjects: 0
Study 24559813 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage with aromatic ginger oil (SMGO)
Number of subjects: 140
Study 24559813 — intervention group
Group type: COMPARATOR
Intervention: Traditional Thai massage (TTM)
Number of subjects: 140
Study 22519705 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 72
Study 22519705 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy (LSH)
Number of subjects: 72
Study 20875371 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 10 mg/day
Number of subjects: 20
Study 20875371 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 45 mg/day
Number of subjects: 20
Study 20875371 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin and pioglitazone co-administration
Number of subjects: 20
Study 20875371 — intervention group
Group type: COMPARATOR
Intervention: linagliptin
Number of subjects: 20
Study 20875371 — intervention group
Group type: COMPARATOR
Intervention: pioglitazone
Number of subjects: 20
Study 18633049 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at the extra 1 point
Number of subjects: 22
Study 18633049 — intervention group
Group type: COMPARATOR
Intervention: Acupressure at the sham point
Number of subjects: 22
Study 16465537 — intervention group
Group type: EXPERIMENTAL
Intervention: TransFix (TF)
Number of subjects: 68
Study 16465537 — intervention group
Group type: COMPARATOR
Intervention: bioscrew (BS)
Number of subjects: 68
Study 14967867 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric diet providing 8 g of CHO/kg of body weight
Number of subjects: 11
Study 14967867 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric diet providing 5 g of CHO/kg of body weight
Number of subjects: 11
Study 14967867 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric diet providing 3 g of CHO/kg of body weight
Number of subjects: 11
Study 10930106 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m2 i.v. weekly
Number of subjects: 99
Study 10930106 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin 100 mg/m2 i.v. followed by 5-fluorouracil 370 mg/m2 i.v. days 1-5, q 28 days
Number of subjects: 99
Study 10930106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m2 i.v. only day 1 + leucovorin 100 mg/m2 i.v. followed by 5-fluorouracil 370 mg/m2 i.v. days 1-3, q 28 days
Number of subjects: 99
Study 8721466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 0
Study 8721466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 0
Study 8721466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine
Number of subjects: 0
Study 8721466 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.25%
Number of subjects: 0
Study 1464655 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone Only group (200 mg testosterone enanthate weekly for 8 weeks)
Number of subjects: 31
Study 1464655 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo/Testosterone group (placebo for first 4 weeks, then 200 mg testosterone enanthate weekly for next 4 weeks)
Number of subjects: 31
Study 1464655 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo injections for first 4 weeks)
Number of subjects: 31
Study 1464655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 6388401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus
Number of subjects: 0
Study 6388401 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 30704533 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation with Small Changes (SC)
Number of subjects: 599
Study 30704533 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation with Large Changes (LC)
Number of subjects: 599
Study 30704533 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 599
Study 30704533 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (SC, LC, C)
Number of subjects: 599
Study 28204882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 50 µg
Number of subjects: 102
Study 28204882 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 50 µg
Number of subjects: 102
Study 28204882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes (sublingual and vaginal)
Number of subjects: 102
Study 24528531 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg bupivacaine plus 8 mg dexamethasone (active group)
Number of subjects: 138
Study 24528531 — intervention group
Group type: COMPARATOR
Intervention: 10 mL saline (placebo group)
Number of subjects: 138
Study 24620839 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance (QA) programme for the CONVERT trial
Number of subjects: 64
Study 22564989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/d plus erlotinib 150 mg/d
Number of subjects: 960
Study 22564989 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib 150 mg/d
Number of subjects: 960
Study 18330698 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg on days 1 and 29) + Exemestane (25 mg once daily for 8 weeks)
Number of subjects: 28
Study 18330698 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin alone (3.75 mg on days 1 and 29)
Number of subjects: 28
Study 18330698 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin + Exemestane
Number of subjects: 28
Study 17336652 — intervention group
Group type: COMPARATOR
Intervention: artemether-lumefantrine
Number of subjects: 774
Study 17336652 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 774
Study 15104612 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview-assisted questionnaire
Number of subjects: 114
Study 15104612 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completion questionnaire
Number of subjects: 114
Study 11574775 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial T(1-2)
Number of subjects: 496
Study 11574775 — intervention group
Group type: EXPERIMENTAL
Intervention: No initial nodal involvement
Number of subjects: 496
Study 11574775 — intervention group
Group type: EXPERIMENTAL
Intervention: No initial chemotherapy exposure
Number of subjects: 496
Study 11574775 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy response
Number of subjects: 496
Study 11574775 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of disease-free interval (DFI)
Number of subjects: 496
Study 11574775 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status (PS) 0-1
Number of subjects: 496
Study 11574775 — intervention group
Group type: EXPERIMENTAL
Intervention: Local-regional recurrence
Number of subjects: 496
Study 11574775 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis excluding DFI
Number of subjects: 496
Study 9448611 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition through a nasoenteric tube with a semi‐elemental diet (n = 18)
Number of subjects: 38
Study 9448611 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition through a central venous catheter (n = 20)
Number of subjects: 38
Study 9448611 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 38
Study 8073865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with bradykinin (1 mg in 10% ethanol in 0.9% saline)
Number of subjects: 12
Study 8073865 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal challenge with bradykinin (1 mg in 10% ethanol in 0.9% saline)
Number of subjects: 12
Study 8073865 — intervention group
Group type: COMPARATOR
Intervention: Control nasal challenge with ethanol/saline vehicle
Number of subjects: 12
Study 8073865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with bradykinin
Number of subjects: 12
Study 3034188 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-vinyl gamma-aminobutyric acid (GVG)
Number of subjects: 0
Study 3034188 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,5,6,7-tetrahydroisoxazolo-(5,4-c)pyridine-3-ol (THIP)
Number of subjects: 0
Study 3034188 — intervention group
Group type: COMPARATOR
Intervention: Nondyskinetic controls
Number of subjects: 0
Study 28744992 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine 1 g/day for 12 weeks
Number of subjects: 90
Study 28701161 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatry intervention (core podiatry care, foot and ankle exercises, orthoses, and footwear provision)
Number of subjects: 43
Study 28701161 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 43
Study 28701161 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatry intervention
Number of subjects: 43
Study 28701161 — intervention group
Group type: COMPARATOR
Intervention: Podiatry intervention and usual care
Number of subjects: 43
Study 25845628 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 35
Study 23040375 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz 'real' pharyngeal stimulation for 10 min (10 patients)
Number of subjects: 20
Study 23040375 — intervention group
Group type: COMPARATOR
Intervention: 'sham' pharyngeal stimulation for 10 min (10 patients)
Number of subjects: 20
Study 20653477 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC 5%
Number of subjects: 20
Study 20653477 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free artificial tears
Number of subjects: 20
Study 19819096 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based decision-making uncertainty management intervention (DMUMI)
Number of subjects: 0
Study 19819096 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16731135 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 120
Study 16731135 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 120
Study 12492740 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole (20 mg b.d.), amoxicillin (750 mg b.d.), metronidazole (250 mg b.d.) for 1 week
Number of subjects: 92
Study 12492740 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole-amoxicillin-metronidazole
Number of subjects: 92
Study 10594201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics plus syringe pressure irrigation of the surgical wound with 300 ml of saline solution.
Number of subjects: 350
Study 10594201 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic systemic antibiotics only (control group).
Number of subjects: 350
Study 9368804 — intervention group
Group type: COMPARATOR
Intervention: 0 g added triglycerides
Number of subjects: 8
Study 9368804 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g added triglycerides
Number of subjects: 8
Study 9368804 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g added triglycerides
Number of subjects: 8
Study 9368804 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g added triglycerides
Number of subjects: 8
Study 9368804 — intervention group
Group type: EXPERIMENTAL
Intervention: All triglyceride amounts (0, 15, 30, 40 g)
Number of subjects: 8
Study 9368804 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g or more added triglycerides
Number of subjects: 8
Study 9368804 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 to 40 g added triglycerides
Number of subjects: 8
Study 7692173 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine regular formulation (RF) 2.5 mg twice daily
Number of subjects: 12
Study 7692173 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine modified release (MR) 5 mg once daily
Number of subjects: 12
Study 7692173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3955199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prenalterol
Number of subjects: 0
Study 3955199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release formulation of prenalterol
Number of subjects: 0
Study 31724351 — intervention group
Group type: EXPERIMENTAL
Intervention: Grain-moxibustion at Zusanli (ST 36) and Weishu (BL 21), 9 cones for each acupoint, once a day for 90 days.
Number of subjects: 60
Study 31724351 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen combined with symptomatic treatment (antiemetic, acid-suppressive, liver-protecting drugs).
Number of subjects: 60
Study 28478653 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-lithium treatment strategy
Number of subjects: 88
Study 28478653 — intervention group
Group type: COMPARATOR
Intervention: Imipramine-lithium treatment strategy
Number of subjects: 88
Study 25415373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed fluence (FF) treatment
Number of subjects: 14
Study 25415373 — intervention group
Group type: COMPARATOR
Intervention: Judged fluence (JF) treatment
Number of subjects: 14
Study 23086494 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerated mastoid air cells (MACs)
Number of subjects: 76
Study 23086494 — intervention group
Group type: COMPARATOR
Intervention: Unregenerated mastoid air cells (MACs)
Number of subjects: 76
Study 21654918 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home training for fathers, skills taught: following the child's lead, imitation with animation, commenting on the child, expectant waiting, duration: 12 weeks, frequency: twice a week
Number of subjects: 18
Study 18490576 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg
Number of subjects: 36
Study 18490576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17042843 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (30 mg x kg(‐1) before induction, 10 mg x kg(‐1) continuously intra‐operatively)
Number of subjects: 50
Study 17042843 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (same volume as magnesium group)
Number of subjects: 50
Study 12895688 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng (200 mg G115)
Number of subjects: 15
Study 12895688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (360 mg GK501)
Number of subjects: 15
Study 12895688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10973403 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary coughing (once every 30 seconds for 15 to 30 minutes)
Number of subjects: 6
Study 10973403 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study 8942562 — intervention group
Group type: EXPERIMENTAL
Intervention: CT > 60 (cadaveric transplant from older donor)
Number of subjects: 24
Study 8942562 — intervention group
Group type: COMPARATOR
Intervention: LT < 50 (living donor transplant from younger donor)
Number of subjects: 24
Study 8942562 — intervention group
Group type: COMPARATOR
Intervention: LT > 60 (living donor transplant from older donor)
Number of subjects: 24
Study 8942562 — intervention group
Group type: COMPARATOR
Intervention: CT < 50 (cadaveric transplant from younger donor)
Number of subjects: 24
Study 1281041 — intervention group
Group type: EXPERIMENTAL
Intervention: L-TAE + ADR
Number of subjects: 289
Study 1281041 — intervention group
Group type: COMPARATOR
Intervention: L-TAE
Number of subjects: 289
Study 6235336 — intervention group
Group type: EXPERIMENTAL
Intervention: Megadoses of vitamins with minerals
Number of subjects: 56
Study 6235336 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 30831308 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (audio session, 26 minutes)
Number of subjects: 148
Study 30831308 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 148
Study 30273343 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide biannual treatment with mass drug administration (MDA)
Number of subjects: 0
Study 30273343 — intervention group
Group type: COMPARATOR
Intervention: Annual treatment of children alone with MDA
Number of subjects: 0
Study 27052303 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC-overload flywheel resistance exercise (12 weeks, 2 times/week; 4 sets of 7 maximal closed-chain knee extensions; <2 min of contractile activity per session)
Number of subjects: 32
Study 27052303 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC-overload flywheel resistance exercise
Number of subjects: 32
Study 27052303 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintaining daily routines)
Number of subjects: 32